BIO-RAD LABORATORIES, INC. acquired AbD Serotec (division of MorphoSys AG) for $62.2 million total consideration (net of cash received of $7.3 million), a transaction completed in January 2013, structured as all cash. The deal was a Carve-out.
AbD Serotec (division of MorphoSys AG) operates in Life Science, is based in Germany / United Kingdom (MorphoSys AG division). AbD Serotec, acquired from MorphoSys AG, brought a comprehensive catalog of research antibodies to Bio-Rad's Life Science business.
We believe that with AbD Serotec's comprehensive catalog of antibodies it complements Bio-Rad's Life Science offerings.
Comprehensive antibody catalog expanding Bio-Rad's Life Science reagent portfolio. Adds antibody reagents to the Life Science segment. Life Science segment
In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for total consideration of $62.2 million (net of cash received of $7.3 million).Bio-Rad Laboratories FY2013 10-K, acquisitions disclosure
Advisory firms were not disclosed for this transaction.